NEW YORK ─ ArcherDx and Premier said today that they have signed a two-part agreement that kicks off a multiyear program to deliver personalized genomic testing to patients.
The goal of the partnership is to help mitigate underutilization of targeted therapies in late-stage cancer patients, ArcherDx said.